AUTHOR=Maddalena A. , Kleinlogel S. TITLE=CRISPR-mediated optogene expression from a cell-specific endogenous promoter in retinal ON-bipolar cells to restore vision JOURNAL=Frontiers in Drug Delivery VOLUME=Volume 3 - 2023 YEAR=2023 URL=https://www.frontiersin.org/journals/drug-delivery/articles/10.3389/fddev.2023.934394 DOI=10.3389/fddev.2023.934394 ISSN=2674-0850 ABSTRACT=Retinitis pigmentosa, an inherited form of retinal degeneration, is characterized by a progressive loss of rods and subsequent degeneration of cones leading to blindness. However, the remaining neural part of the retina (bipolar and ganglion cells) remains anatomically and functionally intact for an extended time. A possible treatment to restore light sensitivity of the retina consists of rendering the remaining retinal cells photosensitive using optogenetic tools like, for example, Opto-mGluR6, a light-sensitive mGluR6 receptor. We have previously demonstrated that AAV vector mediated expression of Opto-mGluR6 in ON-bipolar cells restores visual function in otherwise blind mice. However, classical gene supplementation therapy still suffers from high off-target expression rates and uncontrollable target gene expression levels that may lead to either cytotoxicity or lack of functional restoration. To tackle these issues and achieve cell-specific as well as endogenously controlled Opto-mGluR6 expression, we employed the CRISPR/Cas technology – in particular HITI (Homologous-Independent Target Integration) and MITI (MIcro-homology Targeted Integration) – to knock-in the Opto-mGluR6 gene behind the ON-bipolar cell specific GRM6 promoter. We compared four Cas systems in vitro and we show that SpCas9 for HITI and LbCpf1 for MITI are well suited to promote knock-in. As AAV2-mediated ON-bipolar cell transduction resulted inefficient, we evaluated Exo-AAVs as delivery vehicles and found Exo-AAV1 efficient for targeting ON-bipolar cells. We show that intravitreal injection of Exo-AAV1 carrying vectors promoting MITI significantly improved visual acuity in otherwise blind rd1 mice. We finally confirm and provide a qualitative evaluation of the MITI-mediated knock-in in the correct genomic locus.